Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-adjuvant FOLFOXIRI and Chemoradiotherapy for High Risk Locally Advanced Rectal Cancer
NCT04838496Phase 2Active, not recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Nov 2021
- Primary completion
- Aug 2026
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluorouracil, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and oxaliplatin in rectal cancer, sponsored by Catharina Ziekenhuis. Primary endpoint: Proportion of patients with a pathological complete response (pCR) and sustained clinical complete response (cCR) at 1 year. Started Nov 2021; status: active, not recruiting.
02
Drugs
fluorouracilfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04838496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838496.